PBMCs mononuclear cells

Since initial studies identified opioid receptors on T-lymphocytes (Wybran et al. 1979), the effects of opioids on immune function have been extensively studied. Details of these studies have been exhaustively reviewed (Madden et al. 1991 Adler et al. 1993 Peterson et al. 1998 Donahoe and Vlahov 1998 Roy et al. 2006), and will only be briefly mentioned here. In general, opioids suppress immune function. Peripheral leukocytes, including lymphocytes and peripheral blood mononuclear cells (PBMCs) can express the four major opioid receptor types, MOP, DOP, KOP,... 

PAS Periodic acid-SchiflF reagent PBA Polyclonal B cell activators PBC Primary biliary cirrhosis PBL Peripheral blood lymphocytes PBMC Peripheral blood mononuclear cells PBN N- e f-butyl-a-phenylnitrone PBS Phosphate-buffered saline PC Phosphatidylcholine... 

Interferon-y (IFN-y) mRNA levels were measured in unstimulated peripheral blood mononuclear cell (PBMC) and purified cell populations, using a bDNA assay, to characterize the cell types that contribute to the in vivo increase in IFN-y gene expression seen in HIV infection (Breen et al 1997). IFN-y is a cytokine that can be produced by multiple cell types and is considered to enhance cellular responses by activation of monocytes and macrophages. It is one of the type 1 cy-... 

DPD Biochemical Phenotype Measured in Peripheral Blood Mononuclear Cells (PBMC)... 

Recently, it has been found that NO donors inhibit HIV-1 replication in acutely infected human peripheral blood mononuclear cells (PBMCs), and have an additive inhibitory effect on HIV-1 replication in combination with 3 -azido-3 -deoxythymisylate (AZT) [139, 140]. S-nitrosothiols (RSNOs) inhibit HIV-1 replication at a step in the viral replicative cycle after reverse transcription, but before or during viral protein expression through a cGMP-independent mechanism. In the latently infected U1 cell line, NO donors and intracellular NO production stimulate HIV-1 reactivation. These studies suggest that NO both inhibits HIV-1 replication in acutely infected cells and stimulates HIV-1 reactivation in chronically infected cells. Thus, NO donors may be useful in the treatment of HIV-1 disease by inhibiting acute infection, or reactivating a latent virus. 

Granulocyte differentiation acute promyelocytic leukemia PBMCs (in vivo) Cultured bone marrow mononuclear cells (in vitro) All-trans retinoic acid (ATRA) Promoter analysis of ATRA response genes suggest molecular mechanism underlying ATRA-induced granulocytic differentiation [30]... 

For other efflux transporters such as BCRP (ABCG2), human pharmacokinetic and pharmacodynamic data are currently rare. However, an investigation of the influence of polymorphisms in ABC-transporter genes on the accumulation of nelfinavir in peripheral blood mononuclear cells (PBMCs) revealed no associations between the polymorphisms in the transporters analyzed and the accumulation of nelfinavir in the PBMCs [151], A second study in patients clearly demonstrated an increase in the AUC of the orally and intravenously administered BCRP substrate topotecan when it is given with GF120918, an inhibitor of P-glycoprotein and BCRP [152],... 

For primary isolation of HIV, patient peripheral blood mononuclear cells (PBMC) are collected, the usual inoculum being 106-107 cells. This is the most productive specimen, although virus has been cultured from plasma, semen, tears, saliva, breast milk, and brain tissue. The virus can be cultured from patient specimens at any time in the course of disease, during which the titer changes. Blood contains approximately 60 TCID50% (50% tissue culture infective dose) per milliliter when a person is asymptomatic, and about 7000TCID50/ml in later stages of HIV disease. 

Although cell lines are often used in preclinical studies, it is also important to test a compound on primary cells from the target tissue itself. Because this tissue must be taken from healthy, human volunteers, such tissue is often difficult to obtain in sufficient quantities for many types of assays that require large numbers of cells. In Figure 7.9, normal peripheral blood mononuclear cells (PBMCs) from four unrelated, healthy donors were treated... 

Normal peripheral blood mononuclear cells (PBMCs) from four unrelated, healthy donors treated with fludarabine all four of the control individuals had almost identical dose-response curves. 

To characterize IRIV-elicited immune responses in vitro, we addressed cell proliferation and cytokine expression in peripheral blood mononuclear cell (PBMC) cultures, as well as IRIV effects on dendritic cells (DC). In all experiments, PBMC were obtained from healthy donors and, if needed, further separated into different cell subsets. Finally, cells were cultured in the presence or absence of IRIV as indicated. 

Proliferation assays performed with PBMC cultures from a number of healthy donors demonstrated that IRIV indeed elicited cell proliferation in all tested cultures to an extent variable from donor to donor (Fig. 1 A). Further proliferation assays with CD4+ T-cells or CD8-I- T-cells in coculture with CD 14+ cells demonstrated that IRIV induce CD4+ T-cell proliferation, whereas no proliferation of CD8+ T-cells could be observed (Fig. 1C). Dissection of the CD4+ T-cell population into CD4+CD45RO+ and CD4+CD45RA+ cell subsets pointed to CD4+CD45RO+ cells as proliferative responders (Fig. ID). Importantly, culture of cord blood mononuclear cells in presence of IRIV did not result in major cell proliferation (Fig. IB), underlining antigen experience as prerequisite for IRIV-induced cell proliferation. 

Figure 1 Continued on next page) Immunopotentiating reconstituted influenza virosomes (IRIV) induced antigen specific proliferation of CD4+CD45RO+ cells. (A) Peripheral blood mononuclear cells (PBMQ from healthy donors n=3) were cultured in the absence of stimuli (Neg), in the presence of IRIV (V), and in the presence of control liposomes (L) at the indicated dilutions. Proliferation was measured on day 6 of culture by H-thymidine incorporation. (B) Cord blood mononuclear cells from two donors were cultured in the absence of stimuli (Neg) or in the presence of phytohaemag-glutinin (PHA), concanavalin A (ConA), IRIV (V) or L at the indicated concentrations. Proliferation was measured on day 3 of culture for PHA and ConA cultures and on day 6 for IRIV and L stimulated cultures. (Q Purified CD4+ or CD8+ cells were cocultured with autologous irradiated PBMC in the absence of stimuli (Neg) and in the presence of IRIV (V) at the indicated concentrations. Proliferation was measured on day 6 of culture by H-thymidine incorporation. (D) Purified CD4/CD45RA+ cells and CD4/CD45RO-I-cells were isolated from PBMC of one healthy donor and cocultured with autologous irradiated PBMC in the presence of IRIV (V) or L at the indicated concentration. Proliferation was measured on day 6 of culture by H-thymidine incorporation. Source From Ref 6.

Figure 2 Cytokine gene expression in immunopotentiating reconstituted influenza virosomes (IRIV) stimulated peripheral blood mononuclear cells (PBMC). PBMC were cultured in the presence or absence of IRIV. On days 1 and 2, culture cells were harvested and total cellular RNA was extracted and reverse transcribed. The cDNAs thus obtained were tested in real time polymerase chain reaction assays in the presence of primers specific for the indicated cytokine genes. Source From Refs. 6 and 9.

Figure 3 Cytokine secretion in immunopotentiating reconstituted influenza viro-somes (IRIV)-stimulated peripheral blood mononuclear cells (PBMC). PBMC from a healthy donor were cultured in the absence of stimuli (Neg) or in the presence of IRIV (V, 1 50 diluted) or control liposomes (L, 1 50 diluted). On days 1, 2, and 4 supernatants were harvested and the concentrations of interferon-y (A), GM-CSF (B), TNF-a (C), and interleukin-4 (D) were determined by ELISA. Abbreviations GM-CSF, granulocyte monocyte colony stimulating factor TNF-a, tumor necrosis factor-a. Source From Ref. 6.

ETN, etanercept IL, interleukin INF, infliximab MHC, major histocompatibility complex PBMC, peripheral blood mononuclear cell SNP, single-nucleotide polymorphism. 

---